Indian Pharma Takes Hedging Hit

28 Apr 2008

Mumbai-based drugmaker Wockhardt posted an unexpected 23% fall in quarterly net profit caused by derivatives-related losses. A one-time mark-to-market charge of INR279 million were due to long-term hedging instruments bought to reduce loan interest costs. The hedging covered interest for 50% of its long-term loans.

Click here for ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial